title: Considerations on markers of hepatitis B, C and HIV as indicators of risk behaviour in intravenous drug users.
authors.forename: A
authors.initials: A
authors.lastname: Mele
authors.forename: V
authors.initials: V
authors.lastname: Biancolilli
authors.forename: P
authors.initials: P
authors.lastname: D'Argenio
authors.forename: L
authors.initials: L
authors.lastname: Sagliocca
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000635:transmission; D000293:Adolescent; D000328:Adult; D015415:Biomarkers; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015483:HIV Antibodies / Q000302:isolation & purification*; D015497:HIV-1; D016174:Hepacivirus / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000302:isolation & purification*; D006510:Hepatitis B Antibodies / Q000032:analysis*; D006511:Hepatitis B Antigens / Q000032:analysis*; D018937:Hepatitis C Antibodies; D006801:Humans; D007558:Italy; D008297:Male; D012309:Risk-Taking; D015819:Substance Abuse, Intravenous
chemical_list: D015415:Biomarkers; D015483:HIV Antibodies; D006508:Hepatitis Antibodies; D006510:Hepatitis B Antibodies; D006511:Hepatitis B Antigens; D018937:Hepatitis C Antibodies